Clinical trial of pancreatic cancer diagnostic reagent by blood mRNA examination for practical use
- Conditions
- pancreatic cancer
- Registration Number
- JPRN-UMIN000020758
- Lead Sponsor
- Kanazawa University
- Brief Summary
The sensitivity of the system for PDAC diagnosis was 73.6% (95% confidence interval, 59.7%-84.7%). The specificity for noncancer volunteers, chronic pancreatitis, and patients with intraductal papillary neoplasms was 643.7% (54.6%-73.9%), 63.6% (40.7%-82.8%), and 47.8% (26.8%-69.4%), respectively. Importantly, the sensitivity of this system for both stage I and stage II PDAC was 78.6%(57.1%-100%).
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 205
Not provided
The patients who meet any of the criteria below will be excluded when they are registered. 1. Patients who have been diagnosed with malignancy(excluding pancreatic cancer) within 5 years of the date of the informed consent. 2. Patients who have been or is currently treated with immunosuppressant, oral steroid within one year of the date of the informed consent. 3. Patients who have been treated with anti-cancer drug within 6 months of the date of the informed consent. 4. Patients who are infected with hepatitis B, hepatitis C or other infectious diseases. 5. Patients who are judged to be not appropriate for entry by the trial responsible (collaborative) doctor.
Study & Design
- Study Type
- Observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method